

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

Please complete all required sections to allow your request to be processed.

PATIENT INFORMATION				COVERAGE TYPE
PATIENT LAST NAME	FIRST NAME	INITIAL		<input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER			
STREET ADDRESS	CITY	PROV	POSTAL CODE	ID/CLIENT/COVERAGE NUMBER

PRESCRIBER INFORMATION			
PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION
STREET ADDRESS			<input type="checkbox"/> CPSA <input type="checkbox"/> ACO REGISTRATION NUMBER <input type="checkbox"/> CARNA <input type="checkbox"/> ADA+C <input type="checkbox"/> ACP <input type="checkbox"/> Other
			PHONE
CITY, PROVINCE			
POSTAL CODE			FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED

Notes: Rivaroxaban 10 mg is a benefit for the prophylaxis of venous thromboembolic events in patients who have undergone elective total knee replacement surgery. Coverage is restricted to two 14-day courses of therapy per patient per year. Rivaroxaban 10 mg is also a benefit for the prophylaxis of venous thromboembolic events in patients who have undergone elective total hip replacement surgery. Coverage is restricted to two 35-day courses of therapy per patient per year. Rivaroxaban 10 mg is not eligible for special authorization for coverage beyond these restrictions.

Rivaroxaban 2.5 mg is eligible via special authorization for use in patients with concomitant coronary artery disease and peripheral artery disease. Please see the Rivaroxaban 2.5 mg Special Authorization Request Form (ABC 60081).

Drug requested (check ONE box)

Apixaban (e.g. Eliquis) → complete Section I, II, and/or III
 Dabigatran (e.g. Pradaxa) → complete Section I only
 Edoxaban (e.g. Lixiana) → complete Section I and/or II
 Rivaroxaban 15 mg/20 mg (e.g. Xarelto) → complete Section I and/or II

Section I Prevention of stroke and systemic embolism in atrial fibrillation (AF) patients

a) Does the patient have non-valvular atrial fibrillation (AF)?
 Yes No

b) Please indicate if **warfarin** was used
 Yes → If yes, please indicate if a **two month trial of warfarin** was used
 Yes No, please specify reason _____
 No → If no, please elaborate

a) If the patient has a contraindication to warfarin, provide information regarding the nature of the contraindication

b) If this patient is unable to monitor via INR testing services, please specify the reason

Section II APIXABAN 2.5mg/5mg (e.g. Eliquis), EDOXABAN (e.g. Lixiana) or RIVAROXABAN 15mg/20mg (e.g. Xarelto) for treatment of venous thromboembolic events	Section III APIXABAN 2.5mg (e.g. Eliquis) for prophylaxis of venous thromboembolism (VTE) following elective total hip or total knee replacement surgery
--	---

****Special authorization may be granted for up to six months****

<p>a) Is the request for treatment of deep vein thrombosis (DVT)? <input type="checkbox"/> No <input type="checkbox"/> Yes → date of most recent event _____</p> <p>b) Is the request for treatment of a pulmonary embolism (PE)? <input type="checkbox"/> No <input type="checkbox"/> Yes → date of most recent event _____</p>	<p>a) Has the patient had elective total hip replacement surgery? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>b) Has the patient had elective total knee replacement surgery? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
--	--

PRESCRIBER'S SIGNATURE	DATE (YYYY-MM-DD)	Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009 108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas
------------------------	-------------------	---

ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE FAX YOUR REQUEST

The information on this form is being collected and pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 108 Street, Edmonton AB T5J 3C5.

©The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ©† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 60019 (2020/07)

